As Indian regulators consider emergency approval of a Covid-19 vaccine from the Serum Institute of India, consumer groups are urging authorities to release key documents – such as the clinical trial protocol and study data – amid concerns over transparency and adverse events.

An independent panel of experts set by the Drug Controller General of India meets on Friday to consider the vaccine, which is the Serum Institute’s version of a shot originally co-developed by AstraZeneca (AZN) and the University of Oxford. Earlier this month, the panel delayed its decision while waiting for U.K. regulators to grant emergency use for the AstraZeneca version, which occurred this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]